Document is current

Article History

Received: 18 December 2024

Accepted: 7 April 2025

First Online: 23 April 2025

Declarations

:

: The study protocol received central ethics approval by the research ethics committee of the Vall d’Hebron University Hospital of Barcelona, Spain (PR(AG)480/2018) and was subsequently approved by all participating centres. All participants provided written informed consent.

: Not applicable.

: Beatriz D Ferraz has received speaker fees and support for attending meetings from CSL Behring. Maria Sucena has received consulting fees from Bial, GlaxoSmithKline, CSL Behring and Grifols, speaker fees from AstraZeneca, Bial, CSL Behring, Grifols, GlaxoSmithKline and Novartis, support for attending meetings from Bial, CSL Behring, Grifols and Medinfar, honoraria for participation on advisory board from Bial and CSL Behring.Alice M Turner has received either grants or speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, CSL Behring, Takeda, Vertex, Alpha 1 Foundation and Grifols. José María Hernández- Pérez has received speaker fees from Bial, CSL Behring and GlaxoSmithKline, and support for attending meetings from Grifols and CSL Behring. María Torres-Durán has received either grants or speaker fees from Grifols, IISCIII (Instituto de Investigación Sanitaria Carlos III), IISGS (Instituo de Investigación Sanitaria Galicia Sur), CSL Behring and GlaxoSmithKline, and support for attending meeting from FAES, Bial and Chiesi. Hanan Tanash has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi and Grifols. Carlota Rodríguez-García has received speaker fees from GlaxoSmithKline, Bial, AstraZeneca and CSL Behring, and support for attending meetings from Chiesi and Grifols.Angelo Corsico has received consulting fees from GlaxoSmithKline, Grifols, CSL Behring, Zambon and Bruschettini and support for attending meetings from AstraZeneca and Chiesi. José Luis López-Campos has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Faes, Gebro Pharma, GlaxoSmithKline, Grifols, Menarini and Zambon.Kenneth Chapman has received grant or contracts from BMS, Bellus, AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Takeda and Novartis, consulting fees from AstraZeneca, GSK, Inhibrix, Mereo, Regeneron, Sanofi and Takeda; speaking fees from Valeo, Sanofi, Novartis, GSK and Takeda. Christian F Clarenbach has received consulting fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Daiichi Synkyo, GlaxoSmithKline, Novartis, Sanofi, OM Pharma, MSD, Grifols and Vifor and speaking fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Daiichi Synkyo, GlaxoSmithKline, Novartis, Sanofi, OM Pharma, MSD and Grifols, Vifor.Joana Gomes has received speaker fees from AstraZeneca, GlaxoSmithKline, CSL Behring and Tecnimede and support for attending meetings from Tecnimede. Marc Miravitlles has received grants or contracts from Grifols speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Bial, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols, Zambon, Tabuk Pharmaceuticals, Glenmark Pharmaceuticals, Sanofi/Regeneron and Novartis, support for attending meetings from Boehringer Ingelheim, Menarini, Chiesi, Bial, CSL Behring and Grifols and consulting fees AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, BridgeBio, AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, BridgeBio, Palobiofarma SL, Takeda, Novartis, Beam therapeutics, Novo Nordisk, Sanofi/Regeneron, Zambon, Zentiva and Grifols. The remaining authors report no competing interests.